Please login to the form below

Not currently logged in
Email:
Password:

corticosteroid fluticasone furoate

This page shows the latest corticosteroid fluticasone furoate news and features for those working in and with pharma, biotech and healthcare.

GSK preps COPD filing for asthma pioneer Nucala

GSK preps COPD filing for asthma pioneer Nucala

Aside from Nucala, GSK is pinning its near-term hopes on dolutegravir-based HIV therapies and its closed triple therapy for COPD – delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta

Latest news

  • GSK files first application for triple COPD therapy GSK files first application for triple COPD therapy

    The therapy is a single device delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three most widely-used ... protect its

  • GSK's triple COPD therapy tops Symbicort in phase III trial GSK's triple COPD therapy tops Symbicort in phase III trial

    The phase III FULFIL trial compared the once-daily triple therapy - consisting of corticosteroid fluticasone furoate, long-acting muscarinic antagonist (LAMA) umeclidinium and long-acting beta agonist (LABA) vilanterol - to Symbicort, ... These include

  • GSK brings forward triple COPD therapy filing in US GSK brings forward triple COPD therapy filing in US

    The once-daily therapy developed by GSK and Innoviva (formerly Theravance) comprises corticosteroid fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three

  • FDA panel backs GSK's asthma drug Breo for adults only FDA panel backs GSK's asthma drug Breo for adults only

    The product is sold as Relvar in some markets and is a follow-up to GSK's blockbuster Seretide/Advair product and combines LABA vilanterol with the inhaled corticosteroid (ICS) fluticasone ... furoate. The FDA's panel of experts said the safety and

  • GSK trial throws everything at COPD GSK trial throws everything at COPD

    GSK trial throws everything at COPD. Tests combination of fluticasone furoate, umeclidinium and vilanterol. ... The two companies will test the combination of corticosteroid fluticasone furoate, long-acting muscarinic antagonist (LAMA) umeclidinium and

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics